Please click here to read our COVID-19 policies and resources before your visit or appointment. X
Jump to:  A   |   B   |   C   |   D   |   E   |   F   |   G   |   H   |   I   |   J   |   K   |   L   |   M   |   N   |   O   |   P   |   Q   |   R   |   S   |   T   |   U   |   V   |   W   |   X   |   Y

FDA Delays Decision on Moderna COVID Vaccine for Younger Teens

FDA Delays Decision on Moderna COVID Vaccine for Younger Teens

MONDAY, Nov. 1, 2021 (HealthDay News) -- The U.S. Food and Drug Administration has delayed a decision on whether to approve emergency use of Moderna's COVID-19 vaccine in 12- to 17-year-olds until at least January, the company announced Sunday.

That's because the agency told the company on Friday that it needs more time to assess emerging international data on whether the vaccine increases the risk of a rare heart side effect called myocarditis, Moderna said in a statement.

"On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination. The FDA notified Moderna that this review may not be completed before January 2022," the company said. "The safety of vaccine recipients is of paramount importance to Moderna. The company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence."

Myocarditis is an inflammation of the heart muscle that occurs in rare cases after vaccination, typically after the second shot and particularly in young males.

Several countries have raised concerns that the Moderna vaccine increases the risk of myocarditis in men aged 18-30, and officials in Finland and Sweden have recommended against the use of Moderna for men younger than 30, the Washington Post reported.

But Moderna said Sunday that the "U.S. Centers for Disease Control and Prevention [CDC] and the World Health Organization [WHO] have stated that myocarditis following vaccination with mRNA vaccines has been rare and generally mild."

"It is estimated that over 1.5 million adolescents have received the Moderna COVID-19 vaccine. To date, the observed rate of myocarditis reports in those less than 18 years of age in Moderna's global safety database does not suggest an increased risk of myocarditis in this population," the company statement added. "The company does not yet have access to data from some recent international analyses."

The Moderna vaccine is authorized in the United States for people 18 and older, and the company asked the FDA in June to authorize it for adolescents.

On Sunday, the company also said it will delay seeking FDA authorization of its vaccine for children ages 6-11.

Moderna's main competitor, Pfizer, has fared better with its FDA approvals.

In May, the FDA authorized the emergency use of the Pfizer vaccine for adolescents aged 12 to 15. And on Friday, the agency cleared the vaccine for children aged 5 to 11, administered in two doses of 10 micrograms each. That dose is one-third of the adolescent and adult dose. The Pfizer vaccine is expected to be available for younger children later this week, following a review by CDC vaccine advisors and a likely recommendation for approval from CDC Director Rochelle Walensky.

More information

Visit the U.S. Food and Drug Administration for more on COVID vaccines.


SOURCE: Washington Post

Reviewed Date: --

Find a pediatrician
Infectious Diseases
Dr. Randall Fisher
Dr. Laura Sass
Health Tips
A Simple Way to Keep the Flu Away
Helping Kids Get Over their Fears
What Every Parent Should Know About Immunizations
When Can a Child Wear Contact Lenses
Quizzes
Immunization Quiz
Infant Vaccine Quiz
Vaccine Quiz
Prevention
Prevention Guidelines for Children from Birth to Age 2
Prevention Guidelines for Men 18 to 39
Prevention Guidelines for Women 18 to 39
Prevention Guidelines for Women 40 to 49
Prevention Guidelines for Women 50-64
Prevention Guidelines for Women 65+
Diseases & Conditions
Anatomy of a Child's Brain
Anatomy of the Endocrine System in Children
Anxiety Disorders in Children
Asthma in Children Index
Becker Muscular Dystrophy (BMD) in Children
Bone Marrow Transplant for Children
Brain Tumors in Children
Chemotherapy for Children: Side Effects
Childhood Immunizations
Diphtheria, Tetanus, and Pertussis (DTaP)
Ewing Sarcoma in Children
Firearms
Haemophilus Influenzae Type b (Hib)
Hepatitis B Virus (HBV) in Children
Inflammatory and Infectious Musculoskeletal Disorders
Inflammatory and Infectious Neurological Disorders
Inguinal Hernia in Children
Insect Bites and Children
Kidney Transplantation in Children
Measles, Mumps, and Rubella (MMR)
Meningitis in Children
Mood Disorders in Children and Adolescents
Myasthenia Gravis (MG) in Children
Osteosarcoma (Osteogenic Sarcoma) in Children
Pediatric Blood Disorders
Pneumococcal Infection in Children
Polio (IPV)
Post-Traumatic Stress Disorder (PTSD) in Children
Preparing the School-Aged Child for Surgery
Schizophrenia in Children
School-Aged Child Nutrition
Sports Safety for Children
Superficial Injuries of the Face and Head- Overview
Television and Children
Thalassemia
The Growing Child: 2-Year-Olds
The Heart
The Kidneys
Your Child's Asthma
Your Child's Asthma: Flare-ups

Disclaimer: This information is not intended to substitute or replace the professional medical advice you receive from your child's physician. The content provided on this page is for informational purposes only, and was not designed to diagnose or treat a health problem or disease. Please consult your child's physician with any questions or concerns you may have regarding a medical condition.